The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
|Articles|November 25, 2014
- Immunotherapy (Issue 4)
- Volume 4
- Issue 1
Immunotherapies for Prostate Cancer
Author(s)William K. Oh, MD
William K. Oh, MD, discusses immunotherapies for the treatment of patients with prostate cancer.
Advertisement
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses immunotherapies for the treatment of patients with prostate cancer.
Articles in this issue
almost 12 years ago
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Questionalmost 12 years ago
Programs Prepare for Immuno-Oncology in Clinical Settingalmost 12 years ago
Right Patient for Immunotherapy in NSCLC Exploredalmost 12 years ago
Weight May Affect Toxicity of Immunotherapiesalmost 12 years ago
Adverse Events Associated With Immunotherapy in Lung Canceralmost 12 years ago
Immunotherapy Potential Option in Mesothelioma Treatmentalmost 12 years ago
Potential Immunotherapies for Head and Neck CancersAdvertisement
Related to this article
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5